ClinicalTrials.gg
CompletedNCT04126317CANDELAUpdated Aug 14, 2023Results posted

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

A Phase 2 interventional study of aflibercept and High-dose aflibercept in Neovascular (Wet) Age-Related Macular Degeneration, sponsored by Regeneron Pharmaceuticals. Completed at 46 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
23rd of 66
106 · median 55
Started
2019
with 3 others
Phase 2
7 of 66
none open now
Registered
45th of 66
by date
Lead sponsor
10 of 66
Regeneron Pharmaceuticals

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 23rd largest by enrollment, is one of 4 that started in 2019, is one of 7 in phase 2, and was the 45th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

The primary objectives of the study are to determine the safety of high-dose aflibercept (hereafter referred to as HD) and to determine if HD provides greater intraocular pharmacodynamic (PD) effect and/or longer duration of action compared to intravitreal aflibercept injection (hereafter referred to as IAI).

03

Conditions studied

  • Neovascular (Wet) Age-Related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Men or women ≥50 years of age with active subfoveal choroidal neovascularization (CNV) secondary to nAMD
  • Best Corrected Visual Acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 78 to 24 (Snellen equivalent of 20/32 to 20/320) in the study eye

Key Exclusion Criteria:

  • Evidence of CNV due to any cause other than nAMD in either eye
  • Evidence of diabetic macular edema (DME) or diabetic retinopathy (defined as more than 1 microaneurysm) in either eye in diabetic patients
  • Prior use of IVT anti-VEGF agents (aflibercept, ranibizumab, bevacizumab, brolucizumab, pegaptanib sodium) in the study eye
  • Prior IVT agents in either eye (eg, anti-ang-2/anti-VEGF bispecific monoclonal antibodies, gene therapy)
  • Previous use of intraocular or periocular within 120 days of screening or treatment with an IVT steroid implant at any time in the study eye
  • History of vitreoretinal surgery (including scleral buckling) in the study eye
  • Any other intraocular surgery within 12 weeks (84 days) before the screening visit
  • History of corneal transplant or corneal dystrophy in study eye

NOTE: Other protocol defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    intravitreal aflibercept injection (IAI)

    Treatment-naïve patients with neovascular "wet" age-related macular degeneration (nAMD) randomized in a 1:1 ratio

    Drug: aflibercept

  • Experimental
    High-dose aflibercept (HD)

    Treatment-naïve patients with nAMD randomized in a 1:1 ratio

    Drug: High-dose aflibercept

Interventions

  • Intravitreally (IVT) administered as a liquid formulation in a vial

    Also known as: EYLEA®, BAY86-5321

  • Intravitreally (IVT) administered as a liquid formulation in a vial

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)

    Time frame: Up to Week 44

  2. Number of Participants With at Least One Serious TEAE

    Time frame: Up to Week 44

  3. Number of Participants Without Retinal Fluid in the Center Subfield of Study Eye

    Center subfield=the circular area in 1 millimeter (mm) diameter centered around the center point of the fovea. Without fluid defined as absence of intraretinal fluid (IRF) and/or subretinal fluid (SRF) in the center subfield. Presence of retinal fluid was assessed by spectral domain optical coherence tomography (SD-OCT)

    Time frame: At Week 16

07

Results

Posted Aug 14, 2023

Participant flow

Participant flow — Overall Study
MilestoneIntravitreal Aflibercept Injection (IAI)High-Dose Aflibercept Injection (HD)
Started5353
Completed4951
Not completed42
Withdrew: Adverse event01
Withdrew: Withdrawal by subject41

Outcome measures

PrimaryNumber of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
Time frame:
Up to Week 44
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
ParticipantsIntravitreal Aflibercept Injection (IAI)High-Dose Aflibercept Injection (HD)
Participants with at least 1 Ocular TEAE of the Study Eye2020
Participants with at least 1 Ocular TEAE of the Fellow Eye1313
Participants with at least 1 Non-Ocular TEAE2428
PrimaryNumber of Participants With at Least One Serious TEAE
Time frame:
Up to Week 44
Reported as:
Count of participants · Participants
Number of Participants With at Least One Serious TEAE
ParticipantsIntravitreal Aflibercept Injection (IAI)High-Dose Aflibercept Injection (HD)
Participants with at least 1 Ocular Serious TEAE of the Study Eye12
Participants with at least 1 Ocular Serious TEAE of the Fellow Eye00
Participants with at least 1 Non-Ocular Serious TEAE45
PrimaryNumber of Participants Without Retinal Fluid in the Center Subfield of Study Eye

Center subfield=the circular area in 1 millimeter (mm) diameter centered around the center point of the fovea. Without fluid defined as absence of intraretinal fluid (IRF) and/or subretinal fluid (SRF) in the center subfield. Presence of retinal fluid was assessed by spectral domain optical coherence tomography (SD-OCT)

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Number of Participants Without Retinal Fluid in the Center Subfield of Study Eye
ParticipantsIntravitreal Aflibercept Injection (IAI)High-Dose Aflibercept Injection (HD)
Number of Participants Without Retinal Fluid in the Center Subfield of Study Eye1827

Adverse events

Collected over From first dose up to Week 44 (end of study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravitreal Aflibercept Injection (IAI)0/53 (0%)4/53 (7.5%)14/53 (26.4%)
High-Dose Aflibercept Injection (HD)1/53 (1.9%)7/53 (13.2%)19/53 (35.8%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventIntravitreal Aflibercept Injection (IAI)High-Dose Aflibercept Injection (HD)
Chest painGeneral disorders0/531/53
Non-cardiac chest painGeneral disorders0/531/53
Hepatic encephalopathyNervous system disorders0/531/53
Transient ischaemic attackNervous system disorders0/531/53
Acute left ventricular failureCardiac disorders0/531/53
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/531/53
GlioblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/531/53
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/531/53
ColitisGastrointestinal disorders1/530/53
Small intestinal obstructionGastrointestinal disorders1/530/53
Most frequent other events
Most frequent other events
EventIntravitreal Aflibercept Injection (IAI)High-Dose Aflibercept Injection (HD)
Neovascular age-related macular degeneration Fellow EyeEye disorders3/534/53
Neovascular age-related macular degeneration Study EyeEye disorders4/532/53
Vitreous detachment Study EyeEye disorders3/534/53
FallInjury, poisoning and procedural complications2/533/53
DizzinessNervous system disorders0/533/53
Conjunctival haemorrhage Fellow EyeEye disorders1/533/53
Vitreous detachment Fellow EyeEye disorders3/531/53
Conjunctival haemorrhage Study EyeEye disorders2/533/53

Baseline characteristics

Age, Continuous
Age, Continuous(years)Intravitreal Aflibercept Injection (IAI)High-Dose Aflibercept Injection (HD)Total
Mean77.7 ± 8.2777.0 ± 7.6977.4 ± 7.95
Sex: Female, Male
Sex: Female, Male(Participants)Intravitreal Aflibercept Injection (IAI)High-Dose Aflibercept Injection (HD)Total
Female363066
Male172340
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Intravitreal Aflibercept Injection (IAI)High-Dose Aflibercept Injection (HD)Total
Hispanic of Latino426
Not Hispanic or Latino4951100
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Intravitreal Aflibercept Injection (IAI)High-Dose Aflibercept Injection (HD)Total
White5152103
American Indian or Alaska Native101
Native Hawaiian or Other Pacific Islander011
Other101
Number of Participants without Retinal Fluid in the Center Subfield of Study Eye
Number of Participants without Retinal Fluid in the Center Subfield of Study Eye(Participants)Intravitreal Aflibercept Injection (IAI)High-Dose Aflibercept Injection (HD)Total
Count of participants91019
08

Study locations

46 sites
  • Regeneron Study Site
    Phoenix, Arizona 85020, United States
  • Regeneron Study Site
    Sun City, Arizona 85351, United States
  • Regeneron Study Site
    Encino, California 91436, United States
  • Regeneron Study Site
    Fullerton, California 92835, United States
  • Regeneron Study Site
    Mountain View, California 94040, United States
  • Regeneron Study Site
    Palm Desert, California 92211, United States
  • Regeneron Study Site
    Sacramento, California 95819, United States
  • Regeneron Study Site
    Santa Ana, California 92705, United States
  • Regeneron Study Site
    Colorado Springs, Colorado 80909, United States
  • Regeneron Study Site
    Golden, Colorado 80401, United States
  • Regeneron Study Site
    Waterford, Connecticut 06385, United States
  • Regeneron Study Site
    Fort Lauderdale, Florida 33309, United States
  • Regeneron Study Site
    Fort Myers, Florida 33912, United States
  • Regeneron Study Site
    Lakeland, Florida 33805, United States
  • Regeneron Study Site
    Largo, Florida 33770, United States
  • Regeneron Study Site
    Melbourne, Florida 32901, United States
  • Regeneron Study Site
    Tallahassee, Florida 32308, United States
  • Regeneron Study Site
    Winter Haven, Florida 33880, United States
  • Regeneron Study Site
    Augusta, Georgia 30909, United States
  • Regeneron Study Site
    Marietta, Georgia 30060, United States
  • Regeneron Study Site
    Oak Forest, Illinois 60452, United States
  • Regeneron Study Site
    Hagerstown, Maryland 21740, United States
  • Regeneron Study Site
    Royal Oak, Michigan 48073, United States
  • Regeneron Study Site
    Bloomfield, New Jersey 07003, United States
  • Regeneron Study Site
    Teaneck, New Jersey 07666, United States
  • Regeneron Study Site
    Albuquerque, New Mexico 87102, United States
  • Regeneron Study Site
    Great Neck, New York 11021, United States
  • Regeneron Study Site
    Asheville, North Carolina 28803, United States
  • Regeneron Study Site
    Charlotte, North Carolina 28210, United States
  • Regeneron Study Site
    Columbus, Ohio 43212, United States
  • Regeneron Study Site
    Edmond, Oklahoma 73013, United States
  • Regeneron Study Site
    Portland, Oregon 97221, United States
  • Regeneron Study Site
    Kingston, Pennsylvania 18704, United States
  • Regeneron Study Site
    Ladson, South Carolina 29456, United States
  • Regeneron Study Site
    West Columbia, South Carolina 29169, United States
  • Regeneron Study Site
    Rapid City, South Dakota 57701, United States
  • Regeneron Study Site
    Abilene, Texas 79606, United States
  • Regeneron Study Site
    Arlington, Texas 76012, United States
  • Regeneron Study Site
    Austin, Texas 78705, United States
  • Regeneron Study Site
    Houston, Texas 77030, United States
  • Regeneron Study Site
    The Woodlands, Texas 77384, United States
  • Regeneron Study Site
    Salt Lake City, Utah 84107, United States
  • Regeneron Study Site
    Fairfax, Virginia 22031, United States
  • Regeneron Study Site
    Spokane, Washington 99204, United States
  • Regeneron Study Site
    Morgantown, West Virginia 26506, United States
  • Regeneron Study Site
    Arecibo, 00612, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in May 2021, 18 months.

Results were first posted in Aug 2023, 2 years 3 months after primary completion. A results delay was requested in May 2022.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 18 months is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2019
First posted
Oct 15, 2019
StartActual
Nov 4, 2019
Primary completionActual
May 14, 2021
CompletionActual
Nov 30, 2021
Results delay requested
May 12, 2022
Results first posted
Aug 14, 2023
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04126317
Collaborators
Bayer
Responsible party
Sponsor
First posted
Oct 15, 2019
Start date
Nov 4, 2019
Primary completion
May 14, 2021
Completion
Nov 30, 2021
Results posted
Aug 14, 2023
Last update
Aug 14, 2023

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion